CENTOGENE Smartphone App myLSDapp Now Available in Spanish

Gaucher Disease Monitoring and Treatment Management

Cambridge, MA USA & Rostock, Germany, March 24, 2020 – CENTOGENE (Nasdaq: CNTG) today announced the release of the Spanish language version of myLSDapp, an easy-to-use smartphone app developed for Gaucher disease patients and their physicians. The app is based on CENTOGENE's proprietary biomarker for Gaucher disease Lyso-Gb1, a biomarker with 100% sensitivity, and enables Gaucher patients and physicians to monitor the progress of the disease and the improvement of the patient once he/she has been set on therapy.

myLSDapp combines patients’ medical and quality-of-life information in one simple system. The app enables Gaucher disease patients and their physicians to simultaneously have a clear overview and maximize the outcome of visits. By using myLSDapp patients and physicians can easily request blood tests using CENTOGENE's unique CentoCard®, monitor treatment dosage, and track Lyso-Gb1 levels ─ supporting a deeper understanding of treatment efficacy. International Gaucher Alliance (IGA) has collaborated with CENTOGENE to review the data protection and consent form for myLSDapp. All patients who register with myLSDapp will be informed about the use of their personal data and the purposes of the use.

Dr. Jordi Perez Lopez, Head of Patient Advice and Liaison Service at CENTOGENE commented: "Lyso-Gb1 is not only an important biomarker to support accurate patient diagnosis, but also aids physicians in establishing personalized therapy for Gaucher disease and helps them to determine the optimum treatment dose for each patient. With myLSDapp, Gaucher patients are able to trace their biomarker levels as well as track their overall wellbeing. This unique, collaborative approach enables physicians to have deeper insights and ultimately, enables the best care possible for their patients."

Gaucher disease is one of the most common lysosomal storage disorders affecting approximately 1 in every 40,000 people. It is caused by impaired breakdown of lipids which results in the accumulation of glucosylceramide in many tissues (such as bones, spleen and liver) due to a mutation in the GBA gene.

More information about myLSDapp can be found here.

myLSDapp supports patients and physicians in the management of the disease by collecting data related to the biomarker testing and daily quality-of-life questionnaires. It is not intended for: diagnostics, treatment recommendations, or prescribing dosage changes.